Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial
Journal of the American Veterinary Medical Association · 01.09.2026 · 264 (9) · 1200-1209
DOI: 10.2460/javma.26.02.0098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Veterinary Medical Association, erschienen am 01.09.2026. Verfasst von Caitrin R Lowndes und 5 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glycosides, Horse Diseases, Hyperinsulinism, Insulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To evaluate bexagliflozin for insulin control in horses with naturally occurring insulin dysregulation.
Methods
In a randomized, placebo-controlled crossover study, 10 client-owned Arabian horses with hyperinsulinemia (> 30 μIU/mL) were treated with bexagliflozin (0.03 mg/kg, PO, q 24 h; BEXA03) or placebo control for a 10-day treatment period, crossing over after a 4-day washout. After a further 12-day washout, 8 of the horses were treated with bexagliflozin (0.06 mg/kg, PO, q 24 h; BEXA06) for an additional 7-day treatment period. Oral sugar tests were performed at the beginning of each treatment period (untreated control) and on the final day of each treatment course. Insulin, glucose, triglycerides, and adipokines were compared with mixed-effects linear regression.
Results
Mean resting, maximal (C max ), and area under the curve (AUC) insulin were lower after BEXA06 (resting, 17.6 μIU/mL [95% CI, 5.3 to 29.9 μIU/mL]; C max , 48.4 μIU/mL [95% CI, 24.0 to 72.8 μIU/mL]; AUC, 4,084.0 μIU/mL*min [95% CI, 1,944.4 to 6,223.5 μIU/mL*min]) compared to placebo control (resting, 53.9 μIU/mL [95% CI, 35.0 to 72.7 μIU/mL]; C max , 90.9 μIU/mL [95% CI, 65.0 to 116.9 μIU/mL]; AUC, 9,146.3 μIU/mL*min [95% CI, 6,428.9 to 11,863.7 μIU/mL*min]), but not after BEXA03. Mild hypertriglyceridemia was observed in some horses following treatment with BEXA06 (n = 5), but mean resting triglyceride concentrations were not significantly higher for BEXA06 (49 mg/dL; 95% CI, 30 to 67 mg/dL) compared to the untreated control (32 mg/dL; 95% CI, 26 to 38 mg/dL).
Conclusions
Bexagliflozin (0.06 mg/kg, PO, q 24 h) controlled insulin with minimal impact on serum triglycerides in Arabian horses with naturally occurring insulin dysregulation. Clinical Relevance Treatment with bexagliflozin was effective for the short-term management of naturally occurring insulin dysregulation in horses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Georgia Skelton
Zitieren
APA
Lowndes, C. R., Luethy, D., Skelton, G., Kulp, J., Stefanovski, D., & van Eps, A. W. (2026). Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial. Journal of the American Veterinary Medical Association, 264(9), 1200-1209. https://doi.org/10.2460/javma.26.02.0098
Vancouver
Lowndes CR, Luethy D, Skelton G, Kulp J, Stefanovski D, van Eps AW. Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial. Journal of the American Veterinary Medical Association. 2026;264(9):1200-1209. doi:10.2460/javma.26.02.0098
BibTeX
@article{Lowndes2026,
author = {Lowndes, Caitrin R and Luethy, Daniela and Skelton, Georgia and Kulp, Jeaneen and Stefanovski, Darko and van Eps, Andrew W},
title = {Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial},
journal = {Journal of the American Veterinary Medical Association},
year = {2026},
volume = {264},
number = {9},
pages = {1200--1209},
doi = {10.2460/javma.26.02.0098}
}
EUVIMED